NVO - Novo Nordisk A/S
| Previous Close | 51.88 |
| Open | 51.79 |
| Bid | 53.02 x 1000 |
| Ask | 53.03 x 900 |
| Day's Range | 51.74 - 53.37 |
| 52 Week Range | 41.23 - 53.55 |
| Volume | 3,169,394 |
| Avg. Volume | 1,515,665 |
| Market Cap | 125.117B |
| Beta (3Y Monthly) | 0.64 |
| PE Ratio (TTM) | 21.50 |
| EPS (TTM) | 2.46 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.25 (2.41%) |
| Ex-Dividend Date | 2019-03-22 |
| 1y Target Est | 57.90 |
ReutersUPDATE 2-Novo Nordisk wins U.S. approval for first-of-its-kind oral diabetes drug
The U.S. Food and Drug Administration on Friday approved an oral version of Novo Nordisk's diabetes drug semaglutide, a boost for the Danish drugmaker which hopes to transform the market by offering patients a non-injectable treatment. The world's biggest producer of diabetes drugs already sells an injectable once-weekly version of semaglutide under the brand name Ozempic at nearly $800 per month. Novo did not disclose what it plans to charge for the new oral treatment, called Rybelsus, but said it would be "competitively priced" with other drugs in the same "GLP-1" class of medicines.
- Reuters
UPDATE 2-European shares log fifth week of gains, Novo Nordisk shines
European stocks clocked their fifth straight week of gains on Friday with investors buying into the oil and gas and banking sectors, and Novo Nordisk rising after U.S. approval of its oral diabetes drug. Investors also sought refuge in the so-called defensive sectors such as utilities, real-estate and food and beverages ahead of a week packed with economic data. The United Nations (UN) general assembly will also provide clues on the fallout from attacks on Saudi oil facilities last weekend and indications of a potential meeting between the presidents of Iran and the United States.
- Investor's Business Daily
How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal
Novo Nordisk stock popped Tuesday after an analyst suggested the pharmaceutical company's oral diabetes treatment, semaglutide, could swipe share from Eli Lilly's rival drug, Trulicity.
- Reuters
Factbox: Britain's insulin providers prepare for Brexit fallout
With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade. Below are some of the steps Novo Nordisk, Eli Lilly and Sanofi have taken to prepare for Britain's departure from the European Union on Oct. 31. - All three firms have increased the amount of insulin they are holding inside the country in case a no-deal Brexit leads to customs checks and lengthy delays at Britain's biggest ports of Dover and Folkestone.
- Reuters
With a backup to the backup, insulin makers say they're primed for Brexit
For two men trained as scientists, the bosses of Britain's major insulin providers have had to become experts in ferry schedules, trucking laws and warehouse capacity as they seek to guarantee the supply of life-saving drugs through a chaotic Brexit. With Britain set to leave the European Union within weeks, Pinder Sahota at the world's biggest insulin maker Novo Nordisk, and Sanofi's Hugo Fry have rebuilt operations to withstand the most turbulent of events.
- Benzinga
The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck
Biotech stocks rebounded in last week after declining modestly in the previous week. Some of the drugs that cleared the FDA hurdle this week include Ardelyx Inc (NASDAQ: ARDX )'s constipation drug Ibsrela; ...
CNW GroupNew international study: The hidden burden of diabetes on family members revealed
MISSISSAUGA, ON , Sept. 10, 2019 /CNW/ - People living with diabetes are not the only ones impacted by the condition. Low blood sugar or "lows" as they are often referred to by people living with diabetes, are a well-known side-effect of diabetes treatment, especially when using insulin, and they can be very unpleasant and dangerous if not managed properly.
- Reuters
UPDATE 1-Novo Nordisk to cut insulin prices in the U.S.
Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly. President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were "getting away with murder". Novo will offer a generic version of its most heavily prescribed insulin drug Novolog, used by about a million U.S. patients, at a 50% discount compared to the current list price, the company said in a statement.
- Reuters
Novo Nordisk to cut insulin prices in the U.S.
Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly. President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were "getting away with murder". Novo will offer a generic version of its most heavily prescribed insulin drug Novolog, used by about a million U.S. patients, at a 50% discount compared to the current list price, the company said in a statement.
- Motley Fool
2 Stocks to Watch in September
These two businesses could receive a big boost this month if certain events fall in their favor.
- Zacks
Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M
Vertex (VRTX) inks an all-cash deal to buy privately-held Semma Therapeutic. The acquisition will add pre-clinical type I diabetes candidates to its pipeline.
- Simply Wall St.
We Think Novo Nordisk (CPH:NOVO B) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- American City Business Journals
Drugmaker's $27 million gift will have 'big impact' on NC State
The Novo Nordisk Foundation is investing big into bio-manufacturing research, and at the heart of their new $27 million investment is N.C. State University.
- Zacks
J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?
An Oklahoma judge ruled on Monday that large cap pharmaceutical company Johnson & Johnson (JNJ) would have to pay $572 million to the state.
- Benzinga
Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates
FDA activity remained brisk in August. The FDA gave its nod for a majority of drugs that came up for review, although Vanda Pharmaceuticals Inc. (NASDAQ: VNDA )'s jet lag disorder drug Hetlioz and Sarepta ...
- Zacks
Gilead & Galapagos Close Research & Development Agreement
Gilead (GILD) closes collaboration agreement with Galapagos, per which the latter will receive an upfront license fee payment of $3.95 billion.
- Zacks
Novo Nordisk (NVO) Is Up 2.77% in One Week: What You Should Know
Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
- InvestorPlace
Novo Nordisk Suing Mylan Over Generic Victoza Drug
News of Novo Nordisk suing Mylan is spreading as the two companies prepare for a legal battle.Source: joreks / Shutterstock.com The reason behind the upcoming legal battle has to do with Victoza. This is Novo Nordisk's (NYSE:NVO) drug for treating diabetes. Mylan (NASDAQ:MYL) is looking to market its own generic version of the drug, which is where the rub comes from.Novo Nordisk is seeking to block any efforts by Mylan to market its generic version of Victoza. Having a generic version of the drug available would eat into the revenue the company would make from selling its name brand version.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNovo Nordisk is also seeking to protect its products that still have patent protection. The patents surrounding Victoza will start expiring in July 2021 and the last one will reach its expiration date in March 2033, reports BioSpace.Novo Nordisk suing Mylan specifically has to do with this new drug from the latter being an alleged illegal generic of its own. The company is filing this lawsuit in response to an abbreviated new drug application filed by Mylan with the U.S. Food & Drug Administration. * 10 Marijuana Stocks That Could See 100% Gains, If Not More The lawsuit from Novo Nordisk against Mylan was filed on Monday. This had the company filing its lawsuit with the U.S. District Court for the District of Delaware. Lawsuits can be lengthy procedures, so it will likely be some time before we see the outcome of this one.NVO stock was up 1% and MYL stock was down slightly as of Thursday afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks That Could See 100% Gains, If Not More * 11 Stocks Under $10 to Buy Now * 6 China Stocks to Buy on the Dip As of this writing, William White did not hold a position in any of the aforementioned securities.The post Novo Nordisk Suing Mylan Over Generic Victoza Drug appeared first on InvestorPlace.
- Zacks
Novo Nordisk's Fiasp Gets EC Approval for Label Expansion
Novo Nordisk (NVO) receives EC approval for its fast-acting insulin aspart, Fiasp, for the treatment of diabetes in adolescents and children aged one year or older.
Reuters VideosWhy this diabetes patient fears a no-deal Brexit
Her daily routine is a matter of life and death for Georgina. She is one of Britain's one million diabetics now facing the possibility of medical shortages if the UK plunges out of the European Union without a deal at the end of October. (SOUNDBITE) (English) LONDON RESIDENT AND DIABETES PATIENT, GEORGINA, SAYING: "I can't tell you how worried I am about that. It's life-threatening for me." Her fears have been exacerbated by the British government's own planning for a worst case scenario. The Yellowhammer document suggests the important Calais to Dover trade route could face months of disruption, and the pharmaceuticals industry is particularly vulnerable. That's because three quarters of the 37 million packs of drugs imported from Europe each month, come through the short straits route. Georgina is concerned that the medical supplies she depends on could dwindle. She tests her blood sugar levels four times a day to work out how much of an insulin boost she needs at meal times, in addition to a pump that gives her a low level dosage of insulin 24 hours a day. (SOUNDBITE) (English) LONDON RESIDENT AND DIABETES PATIENT, GEORGINA, SAYING: "I can live without the pump and I can live without all the bits and pieces that go with the pump but I cannot live without the blood testing strips because that's just as important, nearly as important, as having an adequate insulin supply. And the two really go so hand in hand, that's the one thing I don't think people realize." She may take some comfort from private sector preparations. (SOUNDBITE) (English) GENERAL MANAGER OF NOVO NORDISK UK, PINDER SAHOTA, SAYING: "At Novo Nordisk we've been preparing for the last three years, if not more than that, for the worst-case scenario." Pinder Sahota is the UK general manager of the world's biggest insulin maker, Novo Nordisk. (SOUNDBITE) (English) GENERAL MANAGER OF NOVO NORDISK UK, PINDER SAHOTA, SAYING: "So what we've done is we've increased our stock level from - a normal average of stock-holding is six weeks, we've increased that to 18 weeks." That's a warehouse capacity of 3.8 million packs of insulin. Piled up - they'd stand 12 times the height of London's Shard skyscraper. Novo Nordisk has also reserved spaces on alternate ferry routes and air freight if required while exploring other factors such as what to do in the event of fuel shortages. (SOUNDBITE) (English) GENERAL MANAGER OF NOVO NORDISK UK, PINDER SAHOTA, SAYING: "Whilst we can control what we can control, it's the uncertainties of how long will the delays be, that are factors outside our control. But we're doing everything we can to ensure that the patients can continue to get the medicines that they need." But the situation is increasing tensions between industry and the government - and not just around the intricacies of planning for a no-deal. Hugo Fry, UK managing director of France's Sanofi, also says that patients have to be prioritized. (SOUNDBITE) (English) MANAGING DIRECTOR OF SANOFI UK, HUGO FRY, SAYING: "Of course, we're starting to ask ourselves the question... although we're happy to do it, it is starting to weigh on our balance sheet, on our logistics, keeping all this additional stock in the country." And that leads to another frustration - that while the companies like Sanofi and Novo Nordisk dedicate huge resources to such preparation, they are having to spend less time on their normal job - bringing innovative drugs to market.
